Human IL-3Rα (CD123) Antibody - Talacotuzumab Biosimilar

Human IgG1 (S239D/I332E) - CAS #1826831-79-1

ABOUT

Anti-human IL-3R alpha - Talacotuzumab biosimilar - CAS #1826831-79-1

Anti-hIL-3R-hIgG1-DE is a biosimilar antibody of Talacotuzumab, a human interleukin 3 receptor alpha subunit (IL-3Rα, CD123) antibody that blocks IL-3 signaling. This monoclonal antibody (mAb) has reached phase 2/3 in a clinical trial to treat patients with acute myeloid leukemia (AML).

More details More details


Anti-hIL-3R-hIgG1-DE comprises the variable region of Talacotuzumab and the IgG1 constant region of Talacotuzumab mediating high effector functions. 

This antibody can be used together with HEK-Blue™ IL-3 cells for screening and neutralization assays to block IL-3R signaling induced by recombinant human IL-3 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

All products are for research use only, and not for human or veterinary use.

Binding of Anti-IL-3R Talacotuzumab
Binding of Anti-IL-3R Talacotuzumab

SPECIFICATIONS

Specifications

Target

IL-3Rα, CD123

Target species

Human

Applications

Neutralization assay, ELISA, ADCC

Isotype
hIgG1-DE
kappa
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Talacotuzumab
CAS number
1826831-79-1
Synonyms
CSL362
CSL-362
JNJ-56022473
Molecular weight
148 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Endotoxin-free water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-3R-hIgG1-DE
  • Cat code: 
    hil3r-mab18
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20 °C
    Stability: - 20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Talacotuzumab (JNJ-56022473, CSL-362) background

Talacatozumab is a therapeutic, humanized monoclonal antibody (mAb) that targets the human IL-3 receptor alpha subunit (CD123) of the IL-3 receptor [1]. It acts like a receptor antagonist and inhibits IL-3 intracellular signaling [1]. Talacotuzumab was engineered to feature the S239D/I332E double mutation in the Fc region to enhance the binding to CD16 (FcgRIIIa) on the surface of NK cells, to increase the antibody-dependent cellular cytotoxicity (ADCC) [1]. CD123 is overexpressed in multiple hematologic cancers, especially in leukemic stem cells. It is considered an important biomarker of high-risk disease characteristics in acute myeloid leukemia (AML) [2]. Although Talacotuzumab demonstrated promising activity in AML patients [3], later phase 2/3 clinical studies pointed to considerable toxicity [4].

 

References:

1. Busfield, S.J. et al., 2014. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 28(11):2213-2221.
2. Chen Y., et al., 2023. A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. Front Pharmacol. 14: 1151032.
3. Xie, L.H. et al., 2017. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J 7(6):e567.
4. Montesinos P., et al., 2021. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35, 62–74.

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?